Acasă › Obezitate › Illinois

Studii clinice pentru Obezitate în Illinois

56 studii pentru Obezitate caută participanți în Illinois.

Orașe în Illinois

Text oficial al studiului (în engleză)

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Great Lakes Clinical Trials - West Wilson Avenue /ID# 282378, Chicago

În curs de recrutareFaza 2

Vârste de la 18 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT07752979

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Accellacare - DuPage, Lombard

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 30 sept. 2026 · NCT07783802

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

Charter Research LLC - Chicago, Chicago
Flourish Research - Chicago, Chicago
AMR Clinical - Chicago Oak Brook, Oak Brook

În curs de recrutareFaza 2

Vârste de 18 ani și peste · Toate sexele · Actualizat 29 sept. 2026 · NCT07685808

Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss

Christie Clinic, Champaign

În curs de recrutareFaza 2

Vârste de la 18 la 75 · Toate sexele · Actualizat 28 sept. 2026 · NCT07837973

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Great Lakes Clinical Trials, Chicago
Clinical Investigation Spec Gurnee, Gurnee
Endeavor Health, Skokie
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07720271

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Chicago Research Center, Inc, Chicago
Endeavor Health, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07668414

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Cedar Crosse Research Center, Chicago
Northwestern University, Chicago
Endeavor Health - Family Medicine Administration, Evanston
și încă 1

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 28 sept. 2026 · NCT07595549

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Research Site, Champaign
Research Site, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07776509

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Rush University Medical Center, Chicago

În curs de recrutareFaza 3

Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937099

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Ann and Robert Lurie Children's Hospital of Chicago, Chicago
University of Illinois at Chicago, Chicago

În curs de recrutareFaza 3

Vârste de la 6 la 17 · Toate sexele · Actualizat 24 sept. 2026 · NCT06672549

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Rush University Medical Center, Chicago

În curs de recrutareFaza 3

Vârste de la 18 la 70 · Toate sexele · Actualizat 24 sept. 2026 · NCT06937086

AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight

Endeavor Health, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT07339423

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

NorthShore University Health System, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07282600

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Great Lakes Clinical Trials - Ravenswood, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07392190

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

Research Site, Chicago
Research Site, Melrose Park

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07784270

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

Endeavor Health-Northwest Community Healthcare, Arlington Heights
Eagle Clinical Research, Chicago
University of Chicago, Chicago
și încă 2

În curs de recrutareFaza 3

Vârste de la 45 la 99 · Toate sexele · Actualizat 22 sept. 2026 · NCT07037433

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Great Lakes Clinical Trials - Ravenswood, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Great Lakes Clinical Trials - Ravenswood, Chicago

În curs de recrutareFaza 2

Vârste de la 18 la 75 · Toate sexele · Actualizat 22 sept. 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

AURORA-1 Clinical Site, Schaumburg

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

AURORA-2 Clinical Site, Schaumburg

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT07743450

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

Chicago Medical Research LLC, Hazel Crest

În curs de recrutareFaza 3

Vârste de la 18 la 99 · Toate sexele · Actualizat 16 sept. 2026 · NCT07037459

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Elevate Clinical Research, Gurnee
Knownwell, Schaumburg
Endeavor Health, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT07351045

AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

University Of Chicago, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT07571005

AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea

Chicago Research Center, Inc, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 9 sept. 2026 · NCT07571109

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Great Lakes Clinical Trials - Ravenswood, Chicago

În curs de recrutareFaza 2

Vârste de la 18 la 75 · Toate sexele · Actualizat 8 sept. 2026 · NCT06143956

A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight

Walgreens - Store 11760, Oak Park

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT07745504

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Kailera Clinical Site, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Flourish Research - Great Lakes Clinical Trials, Chicago
Endeavor Health, Skokie
Evanston Premier Healthcare Research LLC, Skokie

În curs de recrutareFaza 3

Vârste de la 18 la 99 · Toate sexele · Actualizat 3 sept. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Kailera Clinical Site, Springfield

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT07284875

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

Kailera Clinical Site, Chicago
Kailera Clinical Site, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 1 sept. 2026 · NCT07284979

BRIDGE & Friends Trial

University of Illinois Chicago, Chicago

În curs de recrutareVoluntari sănătoși bineveniți

Vârste de la 50 la 79 · Toate sexele · Actualizat 1 sept. 2026 · NCT07798557

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Endeavor Health, Skokie

În curs de recrutareFaza 3

Vârste de la 18 la 99 · Toate sexele · Actualizat 27 aug. 2026 · NCT07575399

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

Illinois Institute of Technology, Chicago

În curs de recrutareVoluntari sănătoși bineveniți

Vârste de la 21 la 74 · Toate sexele · Actualizat 27 aug. 2026 · NCT07566325

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Research Site, Champaign
Research Site, Chicago

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT07784725

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

În curs de recrutareFaza 2

Vârste de la 7 la 25 · Toate sexele · Actualizat 19 aug. 2026 · NCT05082519

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

Chicago Clinical Research Institute INC, Chicago
Univer Of Illinois at Chicago, Chicago
Eagle Clinical Research, Chicago
și încă 3

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT07567001

Digital InteGrated Behavioral treatmeNt for Comorbid obesITy and deprEssion Among Racial and Ethnic Adults Age 50 and Older

Department of Medicine, Vitoux Program on Aging and Prevention, Chicago

În curs de recrutare

Vârste de la 50 la 74 · Toate sexele · Actualizat 18 aug. 2026 · NCT06636058

AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain

Clinical Investigation Spec Gurnee, Gurnee
Evanston Premier Hlthcr Res, Skokie

În curs de recrutareFaza 3

Vârste de 18 ani și peste · Toate sexele · Actualizat 17 aug. 2026 · NCT07509307

Role of Adiposomes in Endothelial Dysfunction

University of Illinois at Chicago, Chicago

În curs de recrutare

Vârste de la 18 la 50 · Toate sexele · Actualizat 17 aug. 2026 · NCT05199454

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

ACCOMPLISH-1 Research Site, Chicago

În curs de recrutareFaza 3

Vârste de la 18 la 79 · Toate sexele · Actualizat 10 aug. 2026 · NCT07654361

Sursă: ClinicalTrials.gov, date preluate la 3 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.